European Committee Takes a Second Look at Alzheimer's Drug

Changing course, European regulators now say Alzheimer’s treatment Leqembi should be approved
Reversing an earlier decision, European regulators recommended that an Alzheimer’s therapy from Eisai and Biogen should be approved.
European committee takes a second look at Alzheimer's drug and now says it should be approved
A European regulatory committee now recommends approval of the Alzheimer’s treatment lecanemab a few months after rejecting the drug
European watchdog partially approves new Alzheimer's drug
Europe's medicines watchdog on Thursday partially approved a marketing request for a long-awaited new treatment for Alzheimer's disease, reversing an earlier decision not to give it the green light.
EU regulator backs Eisai-Biogen Alzheimer's drug after initial rejection
The European Union's drugs regulator on Thursday recommended approval for Eisai and Biogen's Leqembi in some patients with early Alzheimer's disease, nearly four months after it first rejected the treatment.
EU regulator reverses decision to block Alzheimer's drug lecanemab
The European Union's drugs regulator reversed its decision to block the Alzheimer's drug lecanemab, a treatment aimed at slowing cognitive decline in patients. In July, the Amsterdam-based European Medicines Agency (EMA) denied recommending approval of the drug made by Eisai and Biogen because it considered the risks - especially bleeding and swelling in the brain - to be greater than the potential benefits in a broad population.
Healthier Together: New Alzheimer’s disease warning signs to look out for
A breakthrough in the fight against Alzheimer’s disease may have been made in Seattle. Researchers at the Allen Institute ...
Newser on MSN1h
Researchers Zero In on First, Subtle Phase of Alzheimer's
Alzheimer's disease appears to damage the brain in two phases, and treatment before the latter stage, when "suddenly things ...
Hosted on MSN6h
Structural analysis shows Alzheimer's disease mutation produces 'cottonwool' structures in the brain
An international collaboration led by RIKEN researchers has discovered how unusual spherical structures form in the brains of ...
Brain Autopsies Reveal a Potential New Culprit Behind Alzheimer's
University of Washington-led research, published in 2023, discovered microglia in the brains of people with Alzheimer's ...
Ticker: Biogen Alzheimer’s drug gets second look in EU; Ford takes $165M hit on slow recall
A European regulatory committee now recommends approval of the Alzheimer’s treatment lecanemab a few months after rejecting ...
KARK29m
7 stages of Alzheimer’s
Along with an Alzheimer’s diagnosis comes a flood of questions, both for the person with the disease and their family. The uncertainty of a future with Alzheimer’s is ...
STAT22h
Mild Alzheimer’s patients won’t save Cassava Sciences
As we count down toward the December readout of Cassava Sciences’ simufilam Phase 3 clinical trial in Alzheimer’s disease ...
Biogen’s stock rises after E.U. regulator reverses negative view of Alzheimer’s drug
Biogen’s stock rose 1% Thursday, after Europe’s pharmaceutical regulator issued a positive opinion on the Alzheimer’s disease ...
Medscape4h
Infection Plus Pollution Equals Increased Alzheimer’s Risk
The AD risk factors/hits include high exposure to traffic-related air pollution (TRAP) and infections, as well as factors ...
Money Talks News on MSN5h
Healthy Obesity Linked to Lower Alzheimer's Risk, Study Reveals
A recent study found that relatively healthy obesity may reduce the risk of developing Alzheimer's disease.